Results 141 to 150 of about 192,588 (281)
Analytical performances of the AMPLIQUICK® Respiratory Triplex assay for simultaneous detection and differentiation of SARS-CoV-2, influenza A/B and respiratory syncytial viruses in respiratory specimens. [PDF]
PLoS One, 2022 Mboumba Bouassa RS +4 more
europepmc +1 more source
Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 1036-1046, April 2026.Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu +8 more
wiley +1 more source
Clinical and Public Health Guidelines, Volume 3, Issue 2, April 2026.ABSTRACT Background The Australasian Bronchiolitis Guideline (ABG) provides evidence‐based recommendations for managing one of the most frequent reasons for infant hospitalisation. As traditional guidelines age, they suffer from lack of relevance when new evidence is available but not incorporated.
Kate Loveys +25 more
wiley +1 more source
International Journal of Gynecology &Obstetrics, Volume 173, Issue 1, Page 63-73, April 2026.Abstract Background Respiratory syncytial virus (RSV) is a leading cause of hospitalization and mortality in early infancy. Maternal immunization offers a preventive strategy, but uncertainties regarding safety and economic value have limited its implementation.
Johnatan Torres‐Torres +10 more
wiley +1 more source
Cepheid Xpert® Flu/RSV and Seegene Allplex™ RP1 show high diagnostic agreement for the detection of influenza A/B and respiratory syncytial viruses in clinical practice. [PDF]
Influenza Other Respir Viruses, 2021 Wabe N +6 more
europepmc +1 more source
Immunology, Volume 177, Issue 4, Page 798-809, April 2026.Fully quantitative, mass‐standardised, antibody responses to ten SARS‐CoV‐2 variants show significant variation in immunity profiles or endotypes. The incidence of the complete response to all variants is significantly improved after three vaccinations.
Philip H. James‐Pemberton +6 more
wiley +1 more source
Multivalent Protein Nanorings for Broad and Potent SARS‐CoV‐2 Neutralization
Advanced Healthcare Materials, Volume 15, Issue 10, 13 March 2026.A protein‐only, modular multivalent nanoscaffold displaying 20 anchor points, decorated with two different binders (10 of each), targeting the SARS‐CoV‐2 receptor‐binding domain is presented. The construct self‐assembles into stable, biocompatible, homogeneous nanoparticles, exhibit synergistic binding with fM IC50 values. It also detects spike at 9 ng
Molood Behbahanipour +11 more
wiley +1 more source
Advanced Materials, Volume 38, Issue 13, 3 March 2026.A high‐throughput in vivo mRNA LNP screening platform is developed and employed to screen a large library of 122 mRNA LNPs in vivo for delivery to immune, stromal, and parenchymal cells, identifying promising LNP candidates. A novel small particle flow cytometry‐based protein adsorption analysis method is utilized to interrogate protein corona ...
Alex G. Hamilton +17 more
wiley +1 more source
Advanced Science, Volume 13, Issue 16, 18 March 2026.Cryopreserved lung‐humanized mice overcome the dependency to fresh tissues and permit head‐to‐head profiling of all four human common cold coronaviruses versus SARS‐CoV‐2 infection; the model validates Paxlovid efficacy against HKU1 and, when coupled with human immune‐system engraftment, enables interrogation of lung‐resident human immunity and HKU1 ...
Chunyu Cheng +9 more
wiley +1 more source